Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer

Cancer Gene Therapy

Volumn 11, Issue 11, 2004, Pages 748-756

  Liu, Tie Gang ^a   Yin, James Q ^b,c   Shang, Bo Yang ^a   Min, Zhang ^a   He, Hong Wei ^a   Jiang, Jian Ming ^a   Chen, Fang ^b   Zhen, Yong Su ^a   Shao, Rong Guang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c AltCures Pharmaceutical Inc   (United States)

Author keywords

Apoptosis; Cell cycle regulation; Hdm2; Human breast cancer; SiRNA

Indexed keywords

BRCA1 PROTEIN; CASPASE; CYCLIN DEPENDENT KINASE; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; SURVIVIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; GENE TARGETING; HDM2 ONCOGENE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DNA PRIMERS; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

MAMMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 8444233617     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700753     Document Type: Article

References (39)

1. Yin J, Wang Y. siRNA-mediated gene regulation system: now and the future. Int J Mol Med. 2002;10:355-365.
2. Zamore PD. RNA interference: listening to the sound of silence. Nature Struct Biol. 2001;8:746-750.
3. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15:188-200.
4. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
5. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature. 2002;418:38-39.
6. Yin JQ, Gao J, Shao R, et al. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol. 2003;3:194-204.
7. Xia HB, Mao QW, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo. Nature. 2002;20:1006-1010.
8. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA. 2002;99:1443-1448.
9. Laetitia KL, Arnd H, Aaron C, et al. HdmX stimulates hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sd USA. 2003;100:12009-12014.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
11. Vanessa B, Rosemary EK, Laetitia KL, et al. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol. 2003;5: 754-761.
12. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69: 1237-1245.
13. Wang H. Li N, Dong Y, et al. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer, in vitro and in vivo activities and mechanisms. Clin Cancer Res. 2001;7:3613-3624.
14. Zhang Z, Li M, Wang H, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis. multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA. 2003;100:11636-11641.
15. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer. 1994;58:400-406.
16. Lin SL, Chuong CM, Ying SY. A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCap cells. Biochem Biophys Res Commun. 2001;281:639-644.
17. Li ZJ, Xiong F, Lin QS, et al. Low-temperature increases the yield of biologically active herring antifreeze protein in pichia pastoris. Protein Expr Purif. 2001;21:438-445.
18. Zhong MH, Lu ZM, Foster DA. Down regulating PKC δ provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression. Oncogene. 2002;21:1071-1078.
19. Jason L, Gao DQ, Mariana K, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001;61:3212-3219.
20. Tan YF, Li FX, Piao Y S, et al. Global gene profiling analysis of mouse uterus during the oestrous cycle. Reproduction. 2003;126:171-182.
21. Kralj M, Husnjak K, Korbler T, et al. Endogenous p21 (WAF1/CIP1) status predicts the response of human tumor cells to wild-type p53 and p21 (WAF1/C1P1) overexpression. Cancer Gene Ther. 2003;10:457-467.
22. Lin SL, Chuong CM, Ying SY. A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCap cells. Biochem Biophvs Res Commun. 2001; 281:639-644.
23. Ruth M, Kluck EB, Douglas RG, et al. The release of cytochrome c from mitochondria, a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
24. Cheng EH, Kirsch DG, Clem RJ, et al. Conversion of bcl-2 to a bax-like death effector by caspases. Science. 1997;278:1966-1968.
25. Liang Y, Yan CH, Schor NF. Apoptosis in the absence of caspases 3. Oncogene. 2001;20:6570-6578.
26. Vargason JM, Szittya G, Burgyan J, et al. Size selective recognition of siRNA by an RNA silencing suppressor. Cell. 2003;115:799-811.
27. Janicke RU, Sprengart ML, Wati MR, et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998;273: 9357-9360.
28. Nadeau, G. BRCA1 can stimulate gene transcription by a unique mechanism. EMBO Rep. 2000;1:260-265.
29. Choi YH, Choi BT, Lee WH, et al. Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells. Oncol Rep. 2001;8:1091-1096.
30. Rao S, Lowe M, Herliczek TW, et al. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 1998;17: 2393-2402.
31. Chinnaiyan AM, Orth IC, O'Rourke K, et al. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem. 1996;271:4573-4576.
32. Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 2002;9:1046-1056.
33. Musgrove EA, Swarbrick A, Lee CS, et al. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol. 1998;18:1812-1825.
34. Micheau O, Tschopp J. Induction of TNF receptor 1-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181-190.
35. +-ATPaSe inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem. 2003;134:359-364.
36. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta. 2004;1644:107-113.
37. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int. 2002;1:35-41.
38. Brummelkamp TR, Bernards R, Agamj R. Stable suppression of tumorigenicity by virus-mediated RNA. Cancer Cell. 2002;2:243-247.
39. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;8: 681-686.